Liquid biopsy-based biomarkers for early detection of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality in both men and women in the United States (1). Alarmingly, the incidence of PDAC-related mortality continues to rise and PDAC is projected to be the second deadliest cancer in the U.S. by 2030 (2).